HLB Pharmaceutical Co., Ltd. (047920.KQ) Stock

047920.KQ logo

HLB Pharmaceutical Co., Ltd.

047920.KQSouth Korea
Healthcare

Company profile

HLB Pharmaceutical reported revenue of 205.58 billion KRW for fiscal year 2025, and net income of 4.57 billion KRW. That is a net profit margin of 2.2% for fiscal year 2025. In Q1 2026 (the quarter ended March 31, 2026) revenue was 65.65 billion KRW. In Q1 2026 it reported net income of 720.10 million KRW, against net income of 1.57 billion KRW a year earlier. Our analysis of its filings shows revenue growing from 135.95 billion KRW in fiscal year 2023 to 205.58 billion KRW in fiscal year 2025, 23.0% a year on average. HLB Pharmaceutical reports about 197 full-time employees.

What stands out

  • Revenue rose 50.0% in fiscal year 2025, from 137.08 billion KRW in fiscal year 2024, after a rise of 0.8% the year before.
  • Net income more than doubled in fiscal year 2025, from 2.02 billion KRW in fiscal year 2024.
  • Revenue growth picked up in Q1 2026: up 89.5% from a year before.

Figures from company filings; latest fiscal year ended December 31, 2025.

About HLB Pharmaceutical Co., Ltd.

HLB Pharmaceutical Co., Ltd. researches and develops peptide drugs in South Korea. The company offers skeletal muscle relaxant, tranquilizers, antihistamines, antihypertensive agents, pain relief, antipruritics, astringents, anti-inflammatories, alimentary system drugs, metabolic drugs, ophthalmic agents, local anesthetics, antiarteriosclerotic agents, expectorants, antipyretics, analgesics, antidiabetic drug, chemotherapeutics, peptic ulcer agents, central nervous system drug, antibiotics, digestives, antacids, dental drugs, multivitamins, parasistic skin disese drugs, dermatlogicals, agents for urogenital organ, amino acid agent, antitussive, mucolytic agents, anthelmintics, antidiarrheals, circulatory system drug, vitamins, skin softeners, anti-hemorrhoid drugs, and agents for liver disease. It is also developing CTT-004 for the treatment of ataxia induced by spinocerebellar degeneration; and offers CMO services. The company was formerly known as Mediforum Pharmaceutical Incorporation and changed its name to HLB Pharmaceutical Co., Ltd in October 2020. HLB Pharmaceutical Co., Ltd. was founded in 1998 and is headquartered in Namyangju-si, South Korea.

Largest shareholders

  • Hlb Life Science Co., Ltd.12.16%
  • Yang-Gon Jin1.806 %1.81%
  • Jae-Hyeong Park1.296 %1.30%
  • Yu-rim Jin0.2374 %0.24%
  • In-Hye Jin0.2374 %0.24%

Share of the company, as of September 25, 2026

Leadership

  • Jae-Hyung Park — CEO & Executive Director, 59
  • Kyung-Won Park — Director of Sales, 47
  • Man-Gyu Kim — VP of Strategic Planning & Executive Director, 50

How much revenue does HLB Pharmaceutical make?

HLB Pharmaceutical reported 205.58 billion KRW in revenue for fiscal year 2025, up 50.0% from 137.08 billion KRW in fiscal year 2024. In Q1 2026 revenue was 65.65 billion KRW.

What companies are similar to HLB Pharmaceutical?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Ildong Pharmaceutical Co., Ltd. (249420.KS), Dong-A ST Co., Ltd. (170900.KS), AprilBio Co.,Ltd. (397030.KQ), JW Holdings Corporation (096760.KS).

How has HLB Pharmaceutical's revenue changed over the last 5 fiscal years?

Revenue by fiscal year: FY2021, 62.85 billion KRW; FY2022, 107.48 billion KRW; FY2023, 135.95 billion KRW; FY2024, 137.08 billion KRW; FY2025, 205.58 billion KRW.

Has HLB Pharmaceutical made a profit in recent years?

Net income by fiscal year: FY2021, a loss of 13.23 billion KRW; FY2022, a loss of 11.78 billion KRW; FY2023, a loss of 19.43 billion KRW; FY2024, 2.02 billion KRW; FY2025, 4.57 billion KRW. It reported a net loss in 3 of these 5 years.

Company Information

SectorHealthcare
IndustryMulti-Therapeutic Drug Manufacturing
Employees197
HeadquartersNamyangju-si, South Korea
ExchangeKOSDAQ
TimezoneAsia/Seoul (KST)

Contact & Links

Address
27, Gyeonggang-ro, Namyangju-si, 12244
Phone
82 3 1557 0001
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “HLB Pharmaceutical Co., Ltd. (047920.KQ)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/047920.KQ

LinkedInLinkedInXXYouTubeYouTube